Adia Nutrition Inc. Identifies Over 20 Million Potentialy Improperly Issued Shares

Strategic Insights -

Adia Nutrition Inc., a publicly traded company focused on advancing stem cell therapies, has announced the identification of over 20 million shares that may have been improperly issued as part of an ongoing review of its historical share structure. The shares in question were issued before the current leadership took over and lacked proper documentation or regulatory compliance. The company has confirmed with its legal counsel that they agree with the decision to address this matter and have filed the first case in the appropriate jurisdiction to seek the cancellation of these shares and their return to the company's treasury.

The company's commitment to corporate governance and shareholder value remains paramount, with CEO Larry Powalisz stating, "Our commitment to corporate governance and shareholder value remains paramount... By proactively addressing these historical issues, we are taking decisive steps to rectify past discrepancies and position the company for sustained growth in the regenerative medicine sector."

Key Takeaways:

  • Adia Nutrition Inc. has identified over 20 million shares that may have been improperly issued due to lack of proper documentation or regulatory compliance.
  • The company has filed a case in the appropriate jurisdiction to seek the cancellation of these shares and their return to the company's treasury.
  • The disputed shares were issued before the current leadership took over, and the company is working to rectify the past discrepancies.
  • The company's commitment to corporate governance and shareholder value remains paramount, with a focus on taking proactive steps to rectify historical issues.
  • Adia Nutrition Inc. is focused on advancing stem cell therapies, including Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Sclerosis, as well as treatments for orthopedic conditions, chronic pain, and complex wound repair.
  • The company has two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies.

Statistics:

  • Over 20 million shares may have been improperly issued by Adia Nutrition Inc.
  • The company has filed the first case in the appropriate jurisdiction to seek the cancellation of these shares and their return to the company's treasury.
  • The disputed shares were issued before the current leadership took over.
  • Adia Nutrition Inc. has two key divisions: a supplement division and a medical division.
  • The company has established Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments.

Sources:

  • Adia Nutrition Inc. - Newsfile Corp. - September 4, 2025 - https://www.newsfilecorp.com/release/265004